chromosome 22 open reading frame 23Genealiases: EVG1 · dJ1039K5.6
Q-omics provides the consensus-scored C22orf23 profile across patient tissues and cancer cell-line models. C22orf23 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, C22orf23 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, C22orf23 RNA expression shows 20,966 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, BLCA, and ACC as cancer lineages where C22orf23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C22orf23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C22orf23 survival associations across molecular data types. C22orf23 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C22orf23 RNA expression–survival associations across cancer types. High C22orf23 expression shows unfavorable associations in MESO, LIHC, ACC and THCA, but favorable associations in ESCA and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for C22orf23 RNA expression.
This table summarizes C22orf23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for C22orf23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C22orf23 shows lower tumor expression in BLCA, THCA, UCEC, BRCA and LUAD and higher tumor expression in LIHC. The BLCA box plot shows higher C22orf23 RNA expression in normal versus tumor tissue (log2 FC = −1.000, t-test p = .001).
This table shows molecular features associated with C22orf23 in patient tissues and cancer cell lines. In patient samples, C22orf23 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C22orf23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
